[Fight against cancer of the exocrine pancreas: stagnation or progress? The point of view of the Fondation française de cancérologie digestive (FFCD)].
This paper updates recent trends concerning ductal pancreatic cancer. Knowledge of the cellular mechanisms has improved, and new developments in imaging allow a more accurate staging. Although operative mortality sharply decreased during these last 15 years, the prognosis of pancreatic carcinoma remains dismal, due to late diagnosis, as only one out of ten patients is considered for curative resection. Therapeutic research groups, and among them the Fondation française de cancérologie digestive (FFCD), do their best to develop new therapeutic strategies, including post-operative or preferentially pre-operative radio-chemotherapeutic adjuvant treatments, and to improve chemotherapy in metastatic cancers.
Bedenne
L
L
Service d'hépatogastroentérologie, CHU Le Bocage, Dijon, France.
Villing
A L
AL
Chauffert
B
B
D000230:Adenocarcinoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy / Q000639:trends; D003663:Decision Trees; D005602:France; D006801:Humans; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012955:Societies, Medical; D016896:Treatment Outcome
Lutte contre le cancer du pancréas exocrine: stagnation ou progrès? Le point de vue de la Fondation française de cancérologie digestive (FFCD).